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Abstract
Introduction
• According to the Diagnostic and Statistical Manual of Mental 
Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013), 
“major depressive disorder (MDD) is characterized as a serious illness 
that causes a person to feel deeply sad (or wholly absent of feeling) most 
of the day, nearly every day, for at least two weeks” Depression is the 
leading cause of disability in the United states with an average of 400 
million disability days each year. According to Greenberg at al. (2015), 
this is a much higher number than other mental and physical conditions. 
• Pharmacogenomics is the study of how genes affect an individual’s 
response to medications. Pharmacogenomic testing can be utilized to see 
what medications may be the most effective for a patient with the least 
amount of side effects. Though the utilization of PGx appears beneficial 
in choosing a medication tailored to a patient’s specific genes, the 
clinician should continue to keep age, lifestyle, side effects, cost, and 
comorbid factors in mind while using pharmacogenomics. MDD 
continues to be a significant health condition that impacts people 
regardless or devoid of age, race, or gender. Comorbidities are often 
associated with depression which can make appropriate management 
difficult. The goal of the clinician is to treat these patients with the best 
possible medication choice while mindful of side effects, cost, and 
outcomes. 
• This project focused on medication management rather than other 
treatment modalities. Treatment as usual (TAU) with medication 
management is usually based on practice guidelines and the clinicians 
own experience with certain medications that they believe will help 
control current symptoms. The purpose of this article is to evaluate 
whether PGx demonstrates improved clinical outcomes compared to 
TAU.
• Treatment of depression remains a difficult issue in primary care as 
well as psychiatric medicine. Many of these patients require multiple 
medication trials prior to finding a drug that works to control their 
symptoms without causing unfavorable side effects. This process may 
cause prolonged suffering with depression as well as a decrease in 
quality of life and productivity. The cost and time strain of attempting 
multiple medications continues to be a burden on the patient as well 
as the medical community. 
• Studies on pharmacogenomic testing for MDD are needed to 
demonstrate which medications may have higher efficacy and lower 
cost for both the patient and health care community. Medications are 
uniquely metabolized based on multiple genetic variants which 
pharmacogenomic testing can help identify. One consideration to 
remember while reviewing these finding is that many medications are 
not able to be analyzed with metabolism and genetic variances at this 
time, therefore only medications included in the pharmacogenomic 
testing databases are explored.
Research Question
Literature Review
Applicability to Clinical 
Practice
Acknowledgements Discussion
• The goal of this scholarly project was to evaluate the efficacy of 
pharmacogenomic testing (PGx) versus treatment as usual (TAU) in 
the treatment of major depressive disorder (MDD). According to 
Huang & Lin (2015), MDD is characterized by multiple signs and 
symptoms consisting of mood, vegetative, cognitive, and even 
psychotic behaviors that may cause substantial impairment in the 
functioning and quality of life in an affected individual. This 
literature review consisted of articles found in PubMed, Cochrane, 
and PsychINFO which were extensively reviewed. Articles prior to 
2008 were excluded due to the ever-changing landscape of PGx 
testing. In this review, 18 articles and studies were analyzed. This 
review found favorable outcomes when treatment was guided by PGx 
versus TAU while examining response and remission rates. Although 
data varied, cost effectiveness suggested some positive results with 
PGx although further investigations are needed due to limitations and 
lack of studies. Despite many favorable outcomes, more evidence of 
the effectiveness of PGx is needed to make a concrete 
recommendation that PGx guided treatment is superior to TAU. 
Information in this review will help clinicians decide if this is an 
appropriate option for the treatment of MDD. With continued 
research and ongoing studies this biotechnology is becoming more 
available to the mainstream.
• Terms and mesh headings: depression, major depressive disorder, 
pharmacogenomics, pharmacogenetics, treatment as usual, 
pharmacotherapy, medication, selective serotonin reuptake 
inhibitors, antidepressant, psychiatry and Patient Health 
Questionnaire (PHQ-9)
• As we strive to make mental health topics less taboo, the treatment of 
these diseases will surely increase. With new advances such as PGx, 
guided treatment will continue to be evaluated and hopefully show 
positive outcomes for those suffering from such conditions.
• Treatment of MDD can be quite challenging whether it be by 
psychiatry or family medicine. Being able to review an individual’s 
genetics and how they may react and/or metabolize a drug should 
eliminate time and cost while improving the patient’s mental health. 
Many of these studies show that utilizing PGx has shown greater 
improvement in depression rating scores, less cost associated with 
treatment, and improved quality of life. 
• Exploring and testing the effects of BDNF, cortisol, inflammatory 
markers, and Vitamin D levels have revealed some common links 
between a person’s overall health and MDD. As PGx continues to 
evolve it is likely that we will see more studies evaluating the 
CYP450 system to better understand the metabolism of many of 
these drugs. As some insurance companies are now covering some or 
all costs of these tests, it is presumed that they will become more 
readily available and providers will receive proper education on the 
utilization of PGx.
I would like to personally thank my wonderful advisor Julie Solberg for 
her continuous support and direction during this project. I am also 
grateful for Professor Daryl Sieg for his time and commitment put forth 
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deserved thanks to my peer reviewer Jenna Katnis for so diligently 
evaluating this project. I would like to acknowledge my primary care 
preceptor Elaine Hammond PA-C for continuing to push me forward 
even when I was feeling overwhelmed. Lastly, I am grateful for my 
family for believing in me as I continue through this journey in 
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• In patients with MDD, are medications guided by pharmacogenomic 
testing in the treatment of MDD more effective in achieving response 
and remission of symptoms compared with TAU based on depression 
assessment scales?
• In patients with MDD, does medication management guided by 
pharmacogenomic testing improve cost effectiveness in the 
management of disease compared to TAU?
Pathophysiology of Major Depressive Disorder
• The Diagnostic and Statistical Manual of Mental Disorder (5th ed.; DSM-5; 
American Psychiatric Association, 2013) is widely used by clinicians and 
researchers alike to classify specific mental disorders. According to the 
DSM-V, major depressive disorder (MDD) is diagnosed by having five out 
of the following nine symptoms. Depressed mood most of the day which 
occurs nearly every day, diminished interest or pleasure in almost all 
activities, significant weight loss categorized as 5% of body weight in a 
month, insomnia or hypersomnia, psychomotor agitation or retardation, 
fatigue or loss of energy, feelings of worthlessness or excessive 
inappropriate guilt, diminished ability to think or concentrate, or recurrent 
thoughts of death/suicide or suicide attempt. Five of these nine symptoms 
must be present nearly every day, during a two-week time frame. These 
symptoms need to cause significant stress with social and occupational 
impairment. Also, these episodes may not be attributable to the physiologic 
effects of a substance or another medical condition (American Psychiatric 
Association, 2013).
Pharmacogenomic testing to aid in the treatment of MDD
• In the meta-analysis performed by Rosenblat, Lee, and McIntyre (2018), 
the authors focused on response and remission rate of MDD based on TAU 
and PGx guided treatment. The PGx group had a response rate of 50% 
compared to the unguided group at 36%. The pooled relative risk (RR) for 
treatment response comparing guided versus unguided treatment was 1.36 
or a 95% confidence interval in favor of guided treatment and a (p=0.0006). 
The pooled RR for remission was 1.74 or 95% confidence interval and a 
(p=0.02) which demonstrates statistical significance. The remission rates of 
the guided treatment group were 40% when compared to the unguided 
group at 25%, respectively. 
Cost Effectiveness of Pharmacogenomic Testing
• In a study by Benitez, Cool, and Scotti (2018), the authors evaluated 
administrative claims by health plan members who were treated for 
psychiatric conditions with PGx vs. TAU. These included prescriptions, 
office visits, inpatient, and outpatient services. A major healthcare 
insurance provider which consisted of over 25 million members was 
used. Payments were evaluated for 24 months, pre and post treatment. 
Although only records were reviewed, plan member records evaluated 
had to be at least 18 years old and on a commonly prescribed 
psychotropic medication starting within the past 180 days and without 
other known history of psychotropic medication use. These could be 
members who received TAU or PGx. Statistical significance was 
evaluated by measuring the pre and post treatment cost controlling 
demographics and comorbid conditions. They analyzed 205 members 
treated by PGx and 478 with TAU. There was no significant difference in 
the cohorts when age and gender were observed. Although over the 
period studied the healthcare costs in both groups did rise, the TAU 
increase was higher at $23,132 versus $17,627 (p=0.0004). The cost of 
the PGx test was taken into consideration during these analyses. It was 
noted that the reduced spending was mostly saved by a decrease in 
outpatient services received.
• Studies have shown some promise in the use of 
pharmacogenomic testing for the treatment of MDD. MDD may 
affect a person in many different aspects of their life whether it be 
emotionally, physically, or financially. As the use of 
pharmacogenomic testing in the treatment of MDD continues to 
be explored, the very complicated disease process of MDD that 
may stem from multiple variances in genes must be considered. 
After reviewing the literature, the use of PGx may have a positive 
impact in the treatment of MDD when compared to TAU. As 
advances continue, this will help guide treatment and reduce the 
cost associated with the treatment and management of MDD.
